Serologic evidence of heparin sensitization in cancer patients receiving heparin flushes of venous access devices.
about
The use of fondaparinux for the treatment of venous thromboembolism in a patient with heparin-induced thombocytopenia and thrombosis caused by heparin flushesTreatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Heparin-induced thrombocytopenia among patients of a comprehensive cancer center.
P2860
Serologic evidence of heparin sensitization in cancer patients receiving heparin flushes of venous access devices.
description
1999 nî lūn-bûn
@nan
1999 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Serologic evidence of heparin ...... shes of venous access devices.
@ast
Serologic evidence of heparin ...... shes of venous access devices.
@en
Serologic evidence of heparin ...... shes of venous access devices.
@nl
type
label
Serologic evidence of heparin ...... shes of venous access devices.
@ast
Serologic evidence of heparin ...... shes of venous access devices.
@en
Serologic evidence of heparin ...... shes of venous access devices.
@nl
prefLabel
Serologic evidence of heparin ...... shes of venous access devices.
@ast
Serologic evidence of heparin ...... shes of venous access devices.
@en
Serologic evidence of heparin ...... shes of venous access devices.
@nl
P2093
P356
P1476
Serologic evidence of heparin ...... shes of venous access devices.
@en
P2093
Cullinane AM
Horne MK 3rd
Merryman PK
P2888
P304
P356
10.1007/S005200050303
P577
1999-11-01T00:00:00Z